Gene Express, NeoGenomics combine in Dx commercialisation pact
This article was originally published in Clinica
Personalised medicine specialist Gene Express has licensed its standardised reverse transcription polymerase chain reaction (StaRT-PCR) and standardised expression measurement (SEM) centre technology to clinical reference lab NeoGenomics Laboratories. In return, Gene Express will receive help from NeoGenomics to obtain FDA approval for its lung cancer risk prediction and BCR/ABL gene expression tests. The agreements allow NeoGenomics to commercialise the Gene Express tests, validate any future Gene Express technology for FDA requirements and use StaRT-PCR for its own commercial purposes. Gene Express (Wilmington, North Carolina) expects to submit the lung cancer risk prediction test for FDA approval in Q4 2008 and to begin clinical trials for its BCR/ABL test in Q1 2009. Financial details of the agreements were not revealed.